Pegylated Liposomal Doxorubicin with Vinorelbine in Metastatic Breast Carcinoma

A multicenter phase I-II trial was carried out with the aim of identifying the dose-limiting toxicity and the maximum tolerated dose of vinorelbine (VNR) in combination with pegylated liposomal doxorubicin at a dose of 20 mg/m<sup>2</sup> every 15 days in patients with metastatic breast carcinoma. In the phase I part of the trial, VNR was given at a dose of 20 mg/m<sup>2</sup> every 15 days to a group of 3 patients. In absence of unacceptable toxicity, VNR was escalated to 25, 30, and 35 mg/m<sup>2</sup> for subsequent groups of 3 patients, until the dose-limiting toxicity was reached. No case of palmar-plantar erythrodysesthesia was recorded in these pat…

Treatment of inoperable and/or metastatic biliary tree carcinomas with single-agent gemcitabine or in combination with levofolinic acid and infusional fluorouracil: Results of a multicenter phase II study

Vinorelbine and Cisplatin for the Treatment of Recurrent and/or Metastatic Carcinoma of the Uterine Cervix

<i>Background:</i> To test the clinical activity and toxicity profile of the combination regimen of vinorelbine and cisplatin in a series of patients with carcinoma of the cervix uteri with de novo metastatic disease or recurrent disease after previous therapy. The main aims of the study included analysis of objective response rates, toxicity, and time to progression. <i>Patients and Methods:</i> Forty-two eligible patients were enrolled into the trial and treated with cisplatin 80 mg/m<sup>2</sup> on day 1 and vinorelbine 25 mg/m<sup>2</sup> on day 1 and 8. This regimen was repeated every 21 days upon resolution of toxicity for 3 cycles befor…